Buprenorphine and Office-Based Treatment of Opioid Use Disorders

Spread the love

2016 headerSaturday, October 29, 2016
8:00 a.m. – 5:30 p.m.

  • John A. Renner, Jr., MD, Boston University School of Medicine, Education Section VA Outpatient Clinic, Boston, MA
  • Laura McNicholas, MD, Philadelphia Veterans Administration Medical Center, Philadelphia, PA
  • Michael Fingerhood, MD, John Hopkins School of Medicine, Baltimore, MD

The “Drug Addiction Treatment Act of 2000” created the opportunity to expand treatment for opioid use disorder into the mainstream of medical practice, increase the number of persons treated, and have an important positive public health impact. The legislation specifies several ways in which physicians can be considered qualified to prescribe and dispense buprenorphine in their offices for the treatment of opioid use disorder.

The completion of this training fulfills the requirement prior to notifying the U.S. Department of Health and Human Services (DHHS) of their intention to begin prescribing buprenorphine for the treatment of opioid use disorder. The presentation is designed to train qualified physicians in dispensing or prescribing specifically approved Schedule III, IV, and V narcotic medications for the treatment of opioid addiction in an office-based setting. The goal of this training is to acquire the knowledge and skills needed to provide optimal care to opioid use disorder patients by providing: 1) an overview of opioid use disorder, 2) the efficacy and safety of buprenorphine, 3) process of patient selection, 4) clinical use of buprenorphine, 5) nonpharmacological interventions, 6) medical psychiatric conditions in opioid use disorder patients, 7) office procedures, and 8) special treatment population. In total this eighthour training will include eight separate modules and four case studies. Each of the speakers will be presenting for two hours. The remaining two hours is broken up over the four case studies.

Designated by the DHHS, this training meets the eight-hour requirement and is designed for physicians and other primary care providers to dispense buprenorphine in office practice for treatment of opioid use disorder. Participation in this training will provide physicians with a comprehensive overview of buprenorphine prescribing and its safe and effective use in an office-based setting, such as those in family practice, general internal medicine, psychiatry, pediatrics, adolescent medicine specialists, and Opioid Treatment Programs.

Sponsored in part by the Substance Abuse and Mental Health Services Administration (SAMHSA) and in partnership with the American Academy of Addiction Psychiatry (AAAP), the American Osteopathic Academy of Addiction Medicine (AOAAM) and the American Psychiatric Association (APA)

Funding for this course was made possible (in part) by 1H79T1022022 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government